Treatment options in IgA nephropathy

Nephrology

Volumn 3, Issue 1, 1997, Pages 103-108

  Julian, Bruce A ^a,c   Van Den Wall Bake, A Warmold L ^b  

^a University of Alabama at Birmingham   (United States)

^b ST JOSEPH HOSPITAL   (Netherlands)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

angiotensin converting enzyme inhibitor; fish oil; glucocorticoid; transplantation

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DANAZOL; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; FISH OIL; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; PHENYTOIN; PREDNISOLONE; PREDNISONE;

ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN RESTRICTION; SODIUM RESTRICTION; STEROID THERAPY; TONSILLECTOMY;

EID: 8244254370     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00198.x     Document Type: Conference Paper

References (55)

1. Berger J, Hinglais N. Les depots intercapillaries d'IgA-d'IgG. J. Urol. Nephrol. 1968; 74: 694-5.
2. Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib. Nephrol. 1993; 104: 1-5.
3. D'Amico G, Ragni A, Gandini E, Fellin G. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib. Nephrol. 1993; 104: 6-13.
4. Waldherr R, Rambausek M, Rauterberg W, Andrassy K, Ritz E. Immunohistochemical features of mesangial IgA glomerulonephritis. Contrib. Nephrol. 1984; 40: 99-106.
5. Berthoux FC, Alamartine E, Laurent BL et al. Primary IgA glomerulonephritis and MHC revisited. Contrib. Nephrol. 1993; 104: 54-60.
6. Freedman BI, Spray BJ, Heise ER. HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am. J. Kidney Dis. 1994; 23: 352-7.
7. Hunley TE, Julian BA, Phillips JA III et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int. 1996; 49: 571-7.
8. Yoshidawa N, Ito H, Yoshiara S et al. Macroscopic hematuria in childhood IgA nephropathy. Clin. Nephrol. 1987; 28: 217-21.
9. Wyatt RJ, Julian BA, Woodford SY et al. C4A deficiency and poor prognosis in patients with IgA nephropathy. Clin. Nephrol. 1991; 36: 1-5.
10. Tomino Y, Sakai H. Exacerbating factors in patients with IgA nephropathy. Semin. Nephrol. 1987; 7: 315-17.
11. Droz D, Kramar A, Nawar T, Noel LH. Primary IgA nephropathy: prognostic factors. Contrib. Nephrol. 1984; 40: 202-7.
12. Goumenos D, Ahuja M, Shortland JR, Brown CB. Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol. Dial. Transplant. 1995; 10: 1173-81.
13. Roccatello D, Ferro M, Coppo R et al. Treatment of rapidly progressive IgA nephropathy. Contrib. Nephrol. 1995; 111: 177-83.
14. Lupo A, Rugiu C, Cagnoli L, Zucchelli P, Maschio G. Acute changes in renal function in IgA nephropathy. Semin. Nephrol. 1987; 7: 359-62.
15. Kincaid-Smith P, Ryan GB, Dowling JP, Nicholls K. Acute renal failure in mesangial IgA nephropathy. Contrib. Nephrol. 1984; 40: 182-6.
16. Yoshikawa N, Iijima K, Matsuyama S et al. Repeat renal biopsy in children with IgA nephropathy. Clin. Nephrol. 1990; 33: 160-7.
17. Wyatt RJ, Julian BA, Bhathena DB et al. IgA nephropathy: presentation, clinical course and prognosis in children and adults. Am. J. Kidney Dis. 1984; 4: 192-200.
18. Williams JD, Coles GA. Proteinuria - a direct cause of renal morbidity? Kidney Int. 1994; 45: 443-50.
19. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib. Nephrol. 1995; 111: 184-93.
20. Border WA, Noble NA, Ketteler M. TGF-β: A cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int. 1995; 47: S59-61.
21. Cattran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am. J. Kidney Dis. 1994; 23: 247-54.
22. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol. Dial. Transplant. 1994; 9: 265-9.
23. Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy, J. Clin. Invest. 1995; 96: 2162-9.
24. Schmidt S, Stier E, Hartnung R et al. No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am. J. Kidney Dis. 1995; 26: 727-31.
25. Marre BP, Bernadet Y, Gallois F et al. Relationships between angiotensin 1-converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 690-5.
26. Schmidt S, Schone N, Ritz E, Diabetic Nephropathy Study Group. Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int. 1995; 47: 1176-81.
27. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction of the progression of diabetic and non-diabetic renal diseases: A meta-analysis. Ann. Intern. Med. 1996; 124: 627-32.
28. Coppo R, Roccatello D, Amore A et al. Effects of gluten-free diet in primary IgA nephropathy. Clin. Nephrol. 1990; 33: 72-86.
29. Clarkson AR, Woodroffe AJ. Treatment tentatives in IgA nephropathy. Semin. Nephrol. 1987; 7: 393-98.
30. Yamabe H, Ohsawa H, Inuma H et al. Worse urinary findings after stimulating tonsils in patients with IgA nephropathy. Nephron 1994; 66: 115-16.
31. Lozano L, Garcia-Hoyo R, Egido J, Blasco R, Sancho J. Tonsillectomy decreases the synthesis of polymeric IgA by blood lymphocytes and clinical activity in patients with IgA nephropathy. Proc. EDTA 1985; 22: 800-4.
32. Tamura S, Masuda Y, Inokuchi I, Terasawa K, Sugiyama N. Effect of and indication for tonsillectomy in IgA nephropathy. Acta Otolaryngol. (Stockh.) 1993; 508: 23-8.
33. Clarkson AR, Seymour AE, Woodroffe AJ et al. Controlled trial of phenytoin therapy in IgA nephropathy. Clin. Nephrol. 1980; 13: 215-18.
34. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann. Intern. Med. 1994; 120: 476-84.
35. Cheng IKP, Chan K-W, Chan M-K. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am. J. Kidney Dis. 1989; 14: 361-4.
36. Waldo FB, Wyatt RJ, Kelly DR et al. Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr. Nephrol. 1993; 7: 529-32.
37. Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa M. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 1988; 48: 12-7.
38. Andreoli SP, Bergstein JM. Treatment of severe IgA nephropathy in children. Pediatr. Nephrol. 1989; 3: 248-53.
39. Schena GP, Montenegro M, Scivittaro V. Meta-analysis of randomized controlled trials in patients with IgA nephropathy (Berger's disease). Nephrol. Dial. Transplant. 1990; 5: 47-52.
40. Chen IKP, Chan PCK, Chan MK. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol. Dial. Transplant. 1990; 5: 241-6.
41. Pettersson EE, Rekola S, Berglund L et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin. Nephrol. 1994; 41: 183-90.
42. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): a two-year prospective trial. Clin. Nephrol. 1989; 31: 128-31.
43. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984; 1: 1017-8.
44. Donadio JV, Bergstralh EJ, Offord KP et al. A controlled trial of fish oil in IgA nephropathy. N. Engl. J. Med. 1994; 331: 1194-9.
45. Woo KT, Chiang GSC, Lim CH. Follow-up renal biopsies in IgA nephritic patients on triple therapy. Clin. Nephrol. 1987; 27: 304-5.
46. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two year prospective trial. Clin. Nephrol. 1990; 34: 103-7
47. Lai KN, Lai FM, Li PKT, Vallance-Owen J. Cyclosporin treatment of IgA nephropathy: a short-term controlled trial. BMJ 1987; 295: 1165-8.
48. Chan MK, Kwan SYL, Chan KW, Yeong CK. Controlled trial of antiplatelet agent in mesangial IgA glomerulonephritis. Am. J. Kidney Dis. 1987; 9: 417-21.
49. Tomino Y, Dakai H, Miura M et al. Effect of danazol on solubilization of immune deposits in patients with IgA nephropathy. Am. J. Kidney Dis. 1984; 4: 135-40.
50. Miura M, Endoh M, Nomoto Y, Sakai H. Long-term effect of urokinase therapy in IgA nephropathy. Clin. Nephrol. 1989; 32: 209-16.
51. Dato M, Takayama K, Kojima H, Koshikawa S. Sodium cromoglycate therapy in IgA nephropathy: a preliminary short-term trial. Am. J. Kidney Dis. 1990; 15: 141-6.
52. Deteix P. Prospective controlled therapeutic trial with diamino diphenyl-sulfone-dapsone in primitive IgA nephropathy. Proc. 9th Int. Congr. Nephrol. Los Angeles, CA, 1984: 83A.
53. Berger J. Recurrence of IgA nephropathy in renal allografts. Am. J. Kidney Dis. 1988; 12: 371-2.
54. Hartnung R, Livingston B, Excell L, Disney A, Woodroffe AJ. Recurrence of IgA deposits/disease in grafts. An Australian registry survey 1980-1990. Contrib. Nephrol. 1995; 111: 13-17.
55. Lim EC, Chai D, Gjertson DW, Koka P, Terasaki PI. In vitro studies to explain high renal allograft survival in IgA nephropathy patients. Transplantation 1993; 55: 996-9.